Last reviewed · How we verify

Insulin (Pork) (INSULIN PORK)

FDA-approved approved Recombinant protein Quality 15/100

Insulin Pork is a marketed insulin therapy that binds to insulin receptors to facilitate glucose uptake and lower blood sugar levels, competing in a well-established market with other insulin products. Its key strength lies in its long-standing use and familiarity among patients and healthcare providers, supported by a key composition patent expiring in 2028. The primary risk is the intense competition from same-class drugs such as insulin human, insulin beef, insulin lispro, insulin aspart, and insulin glulisine, which have been approved and widely used since the 1980s and 1990s.

At a glance

Generic nameINSULIN PORK
ModalityRecombinant protein
Therapeutic areaMetabolic
PhaseFDA-approved
First approval1966

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: